Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice
Matthias Pinter, Bernhard Scheiner, David J. Pinato
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 8, pp. 760-770
Closed Access | Times Cited: 57

Showing 1-25 of 57 citing articles:

Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
Kang Wang, Yan‐Jun Xiang, Hongming Yu, et al.
Nature Medicine (2024) Vol. 30, Iss. 3, pp. 708-715
Closed Access | Times Cited: 52
Targeting SRSF10 might inhibit M2 macrophage polarization and potentiate anti‐PD‐1 therapy in hepatocellular carcinoma
Jialiang Cai, Lina Song, Feng Zhang, et al.
Cancer Communications (2024) Vol. 44, Iss. 11, pp. 1231-1260
Open Access | Times Cited: 23
FOXM1 promotes malignant biological behavior and metabolic reprogramming by targeting SPINK1 in hepatocellular carcinoma and affecting the p53 pathway
Xu Ding, Jinjun Shi, Zhengqing Lei, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2025), pp. 167673-167673
Closed Access | Times Cited: 3
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction
Claudia Angela Maria Fulgenzi, Bernhard Scheiner, Antonio D’Alessio, et al.
JAMA Oncology (2024) Vol. 10, Iss. 9, pp. 1253-1253
Closed Access | Times Cited: 10
Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: A phase II study
Mingyue Cai, Wensou Huang, Wei Liang, et al.
Liver International (2024) Vol. 44, Iss. 4, pp. 920-930
Closed Access | Times Cited: 9
Editorial: High Baseline ALT Level Confers Risk of Hepatic Adverse Events During Immune Checkpoint Inhibitors Treatment—A Call for Caution
Zehua Zhao, Yu‐Chen Fan
Alimentary Pharmacology & Therapeutics (2025)
Closed Access | Times Cited: 1
Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial
Xiaoyang Hong, Yongjian Guo, Wenbo Shi, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Role of hepatotropic viruses in promoting hepatocellular carcinoma—current knowledge and recent advances
Piotr Starnawski, Klaudia Nowak, Zuzanna Augustyn, et al.
Medical Oncology (2025) Vol. 42, Iss. 4
Closed Access | Times Cited: 1
Tumor-infiltrating T lymphocytes: A promising immunotherapeutic target for preventing immune escape in cholangiocarcinoma
Sijia Hua, Xinyi Gu, Hangbin Jin, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 177, pp. 117080-117080
Open Access | Times Cited: 8
Advanced lung cancer inflammation index predicts overall survival of hepatocellular carcinoma after hepatectomy
Yuan-Zhang Wen, Gao‐Min Liu, Jia-Peng Liao, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 7
Combined hepatocellular-cholangiocarcinoma: from genesis to molecular pathways and therapeutic strategies
Simona Gurzu, Rita Szodorai, Ioan Jung, et al.
Journal of Cancer Research and Clinical Oncology (2024) Vol. 150, Iss. 5
Open Access | Times Cited: 6
SiRNA-HIF-1α delivered by attenuated Salmonella enhances the efficacy of Lenvatinib against hepatocellular carcinoma
Pengfei Chen, Yanling Wang, Xingshu Zhu, et al.
International Immunopharmacology (2024) Vol. 130, pp. 111728-111728
Closed Access | Times Cited: 5
Inhibition of KIF20A enhances the immunotherapeutic effect of hepatocellular carcinoma by enhancing c-Myc ubiquitination
Shujia Chen, Lili Zhao, Jie Liu, et al.
Cancer Letters (2024) Vol. 598, pp. 217105-217105
Closed Access | Times Cited: 5
Targeted delivery of CCL3 reprograms macrophage antigen presentation and enhances the efficacy of immune checkpoint blockade therapy in hepatocellular carcinoma
Muqi Liu, Linzhe Li, Lu Cao, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 2, pp. e010947-e010947
Open Access
TMEM115 as an Oncogenic and Immunological Biomarker in Hepatocellular Carcinoma
Ping‐Ping Sun, Haiyan Xu, Chengfeng Guo, et al.
Liver International (2025) Vol. 45, Iss. 4
Closed Access
Hafnium Metal–Organic Framework-Based Glutamine Metabolism Disruptor For Potentiating Radio-Immunotherapy in MYC-Amplified Hepatocellular Carcinoma
Haofan Hu, Shangwu Ning, Furong Liu, et al.
ACS Applied Materials & Interfaces (2025)
Closed Access
Traditional Chinese medicine and natural products in management of hepatocellular carcinoma: Biological mechanisms and therapeutic potential
Yuqiang Xun, Guang Chen, Guping Tang, et al.
Pharmacological Research (2025), pp. 107733-107733
Open Access
Study protocol: Fecal Microbiota Transplant combined with Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma who failed to achieve or maintain objective response to Atezolizumab/Bevacizumab – the FAB-HCC pilot study
Katharina Pomej, Adrian Frick, Bernhard Scheiner, et al.
PLoS ONE (2025) Vol. 20, Iss. 4, pp. e0321189-e0321189
Open Access
Increased expression of DNAJC7 promotes the progression of hepatocellular carcinoma by influencing the cell cycle and immune microenvironment
Jiaxing Chen, Zhizhao Yang, Yongqiang Cui, et al.
Journal of Cancer Research and Clinical Oncology (2025) Vol. 151, Iss. 5
Open Access
Self-delivery photothermal-boosted-nanobike multi-overcoming immune escape by photothermal/chemical/immune synergistic therapy against HCC
Huizhen Yang, Weiwei Mu, Shijun Yuan, et al.
Journal of Nanobiotechnology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 3
Programmed Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor and Monitor of Response to Atezolizumab plus Bevacizumab Treatment in Patients with Hepatocellular Carcinoma
Takuto Nosaka, Yosuke Murata, Yu Akazawa, et al.
Cancers (2024) Vol. 16, Iss. 9, pp. 1785-1785
Open Access | Times Cited: 3
Immune Microenvironment and the Effect of Vascular Endothelial Growth Factor Inhibition in Hepatocellular Carcinoma
Kyoko Oura, Asahiro Morishita, Tomoko Tadokoro, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 24, pp. 13590-13590
Open Access | Times Cited: 3
Genetic Insights into Sarcomatoid Hepatocellular Carcinoma: Critical Role of ARID2 in Pathogenesis and Immune Feature
Naoshi Nishida
Clinical and Molecular Hepatology (2025)
Open Access
Transforming Hepatocellular Carcinoma Treatment in Lower Income Countries
Channa R. Jayasekera, Chrishanthi Rajasooriyar, Clayton Richards, et al.
Mayo Clinic Proceedings (2025)
Closed Access
Improving immunotherapy for the treatment of hepatocellular carcinoma: learning from patients and preclinical models
Romain Désert, Fabio Gianonne, Antonio Saviano, et al.
npj gut and liver. (2025) Vol. 2, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top